Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 6/20 | 0.45 |
| ▸ | GRM5 | P41594 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25261381 | 1.00 | GSK3B (0.51) | GSK3BBRAFVNN1GRM5TSHR | |
| SCHEMBL25310344 | 0.88 | GSK3B (0.51) | GSK3BBRAFVNN1GRM5ROCK2 | |
| SCHEMBL30460403 | 0.88 | GSK3B (0.51) | GSK3BBRAFVNN1GRM5ROCK2 | |
| SCHEMBL30460433 | 0.85 | GSK3B (0.51) | GSK3BBRAFVNN1GRM5 | |
| SCHEMBL25310776 | 0.85 | GSK3B (0.51) | GSK3BBRAFVNN1GRM5 | |
| SCHEMBL25311461 | 0.85 | GSK3B (0.54) | GSK3BBRAFVNN1GRM5 | |
| SCHEMBL30460379 | 0.85 | GSK3B (0.54) | GSK3BBRAFVNN1GRM5 | |
| SCHEMBL25260579 | 0.82 | GSK3B (0.51) | GSK3BBRAFVNN1GRM5 | |
| SCHEMBL30460566 | 0.82 | GSK3B (0.51) | GSK3BBRAFVNN1GRM5 | |
| SCHEMBL25310003 | 0.80 | GSK3B (0.51) | GSK3BVNN1GRM5HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101013-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LEADXPRO AG (CH) | 2025-03-27 | — | — | US | disclosed |
| EP-4466267-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LeadXpro AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| CN-118574828-A | Functionalized aminothiazoles | 里德埃克斯普洛股份公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023139132-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LEADXPRO AG (CH) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101013-A1 | FUNCTIONALIZED AMINOTHIAZOLES | ADORA2B, RB1, ADORA3 | GSK3B 3066/4885BRAF 459/4885VNN1 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.